San Raffaele
Chemotherapy for pancreatic cancer in Italy typically costs between $10,000 and $16,000. The total price depends on the drug regimen, cancer stage, and chosen facility tier. Patients save around 63% compared to the US, where similar treatment costs $35,000 on average. Inclusions generally cover medical consultations, chemotherapy administration, and necessary laboratory tests.
Bookimed Expert Insight: Choosing a research-focused institution like San Raffaele in Milan offers significant value. This hospital holds IRCCS accreditation from the Italian Ministry of Health for its research. While chemotherapy costs there range from $15,500 to $26,600, patients access cutting-edge protocols. The facility treats 300,000 patients annually and was recognized as a World's Best Hospital by Newsweek.
Why do patients choose Italy for chemotherapy for pancreatic cancer?
Access advanced Chemotherapy for pancreatic cancer solutions in trusted clinics .
| Italy | Turkey | Austria | |
| Chemotherapy for pancreatic cancer | from $10,000 | from $1,500 | from $10,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Chemotherapy for pancreatic cancer upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Chemotherapy for pancreatic cancer and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Chemotherapy for pancreatic cancer journey.
Day 1
Day 2
Day 3-5
Week 2
Weeks 3-6
Week 7
Week 8-12
Weeks 12-16
Week 17 onwards
Please note that each patient"s journey is unique and the timeline may vary based on the patient"s response to treatment.
Standard chemotherapy protocols in Italy for pancreatic cancer follow Italian Medical Oncology Association (AIOM) guidelines. Fit patients typically receive intensive regimens like PAXG or FOLFIRINOX. For elderly or less fit patients, Gemcitabine combined with nab-paclitaxel or Gemcitabine monotherapy is the primary clinical standard for metastatic and adjuvant care.
Bookimed Expert Insight: The PAXG regimen is a unique Italian innovation that shows superior event-free survival in neoadjuvant settings compared to mFOLFIRINOX. Patients seeking this specific protocol should look at IRCCS-accredited research hospitals like San Raffaele in Milan. These institutions often provide faster access to the latest AIFA-approved combinations than general public hospitals.
Patient Consensus: Patients often emphasize starting FOLFIRINOX as early as possible while physical fitness is high. Many note that major centers in Milan offer faster treatment initiation compared to other European systems.
Patients should plan to stay in Italy for 7 to 14 days per chemotherapy cycle. This timeframe allows for treatment, recovery, and essential monitoring. Major post-operative care requires a longer commitment. Expect 2 to 6 weeks in the country before safe air travel is permitted.
Bookimed Expert Insight: Research hospitals like San Raffaele in Milan manage over 52,000 operations annually. Their high patient volume suggests efficient recovery protocols. These centers often combine research with treatment. This helps patients reach travel-readiness milestones faster than smaller facilities.
The most experienced Italian centers for pancreatic cancer chemotherapy and multidisciplinary care are located in Milan and Verona. Ospedale San Raffaele and Istituto Europeo di Oncologia (IEO) lead in oncology research. These facilities utilize specialized Tumor Boards to coordinate systemic treatments and surgical interventions.
Bookimed Expert Insight: San Raffaele in Milan performs over 52,000 operations annually and serves 300,000 patients. This massive scale allows their oncology department to manage rare pancreatic subtypes. Their status as an IRCCS ensures patients receive therapies based on the latest ministerial research standards. Use this high volume as a proxy for specialized technical skill.
Patient Consensus: Patients emphasize seeking centers treating at least 20 cases annually for better outcomes. Many recommend checking trial enrollment dates early to avoid missing cutting-edge treatment windows.
Italian pancreatic cancer guidelines (AIOM) classify neoadjuvant chemotherapy as the mandatory standard for borderline resectable (BRPC) and locally advanced (LAPC) cases. This preoperative approach aims to shrink tumors near major vessels, treat micrometastatic disease early, and increase the probability of successful R0 surgical resections.
Bookimed Expert Insight: While standard protocols favor surgery for resectable cases, high-volume Italian centers like Ospedale San Raffaele increasingly apply neoadjuvant therapy more broadly. Their IRCCS research status allows patients access to intensive trials like CASSANDRA, which may explain why Italian R0 resection rates often exceed global averages.
Patient Consensus: Patients emphasize that neoadjuvant treatment requires stamina for 3 to 6 months of intensive chemotherapy. Many recommend seeking a second opinion if a surgeon pushes for immediate surgery without considering preoperative tumor shrinkage.